Involvement of E-cadherin, β-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma

Summary Background  A key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may be viewed as a consequence of the disruption of homeostatic mechanisms in the skin of the original site. Objectives  To investigate...

Full description

Saved in:
Bibliographic Details
Published in:British journal of dermatology (1951) Vol. 157; no. 6; pp. 1212 - 1216
Main Authors: Tucci, M.G., Lucarini, G., Brancorsini, D., Zizzi, A., Pugnaloni, A., Giacchetti, A., Ricotti, G., Biagini, G.
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Publishing Ltd 01-12-2007
Blackwell
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Summary Background  A key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may be viewed as a consequence of the disruption of homeostatic mechanisms in the skin of the original site. Objectives  To investigate whether dysregulation of cell motility (Cdc42 expression), escaping the control of cell–cell and cell–matrix interactions (E‐cadherin, β‐catenin expression), enhances melanoma progression, and whether chemokine receptors (CXCR4) mediate cell migration and activation during invasion and metastasis development. Methods  The immunohistochemical expression of Cdc42, E‐cadherin, β‐catenin and CXCR4 was investigated in 30 patients with surgically treated nodular melanoma, 18 alive and disease free and 12 with a fatal outcome due to metastatic disease. Results  E‐cadherin expression was significantly reduced (P < 0·05) and cytoplasmic β‐catenin was increased in the patients who had died compared with disease‐free individuals, while membrane expression of β‐catenin was similar in the two groups. Patients with fatal outcome had increased Cdc42 (P < 0·01) and CXCR4 (P < 0·05). In this group a positive correlation was found between melanocytic Cdc42 expression and Breslow thickness (r = 0·598, P < 0·05) and between CXCR4 expression and Breslow thickness (r = 0·583, P < 0·05). Conclusions  Findings suggest that primary cutaneous melanoma with a high Breslow thickness is characterized by tumour cells with high motility and invasion ability, in line with the hypothesis that low E‐cadherin levels and overexpression of Cdc42 and CXCR4 could be prognostic markers of poor outcome.
AbstractList Summary Background  A key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may be viewed as a consequence of the disruption of homeostatic mechanisms in the skin of the original site. Objectives  To investigate whether dysregulation of cell motility (Cdc42 expression), escaping the control of cell–cell and cell–matrix interactions (E‐cadherin, β‐catenin expression), enhances melanoma progression, and whether chemokine receptors (CXCR4) mediate cell migration and activation during invasion and metastasis development. Methods  The immunohistochemical expression of Cdc42, E‐cadherin, β‐catenin and CXCR4 was investigated in 30 patients with surgically treated nodular melanoma, 18 alive and disease free and 12 with a fatal outcome due to metastatic disease. Results  E‐cadherin expression was significantly reduced (P < 0·05) and cytoplasmic β‐catenin was increased in the patients who had died compared with disease‐free individuals, while membrane expression of β‐catenin was similar in the two groups. Patients with fatal outcome had increased Cdc42 (P < 0·01) and CXCR4 (P < 0·05). In this group a positive correlation was found between melanocytic Cdc42 expression and Breslow thickness (r = 0·598, P < 0·05) and between CXCR4 expression and Breslow thickness (r = 0·583, P < 0·05). Conclusions  Findings suggest that primary cutaneous melanoma with a high Breslow thickness is characterized by tumour cells with high motility and invasion ability, in line with the hypothesis that low E‐cadherin levels and overexpression of Cdc42 and CXCR4 could be prognostic markers of poor outcome.
A key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may be viewed as a consequence of the disruption of homeostatic mechanisms in the skin of the original site. To investigate whether dysregulation of cell motility (Cdc42 expression), escaping the control of cell-cell and cell-matrix interactions (E-cadherin, beta-catenin expression), enhances melanoma progression, and whether chemokine receptors (CXCR4) mediate cell migration and activation during invasion and metastasis development. The immunohistochemical expression of Cdc42, E-cadherin, beta-catenin and CXCR4 was investigated in 30 patients with surgically treated nodular melanoma, 18 alive and disease free and 12 with a fatal outcome due to metastatic disease. E-cadherin expression was significantly reduced (P < 0.05) and cytoplasmic beta-catenin was increased in the patients who had died compared with disease-free individuals, while membrane expression of beta-catenin was similar in the two groups. Patients with fatal outcome had increased Cdc42 (P < 0.01) and CXCR4 (P < 0.05). In this group a positive correlation was found between melanocytic Cdc42 expression and Breslow thickness (r = 0.598, P < 0.05) and between CXCR4 expression and Breslow thickness (r = 0.583, P < 0.05). Findings suggest that primary cutaneous melanoma with a high Breslow thickness is characterized by tumour cells with high motility and invasion ability, in line with the hypothesis that low E-cadherin levels and overexpression of Cdc42 and CXCR4 could be prognostic markers of poor outcome.
BACKGROUNDA key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may be viewed as a consequence of the disruption of homeostatic mechanisms in the skin of the original site.OBJECTIVESTo investigate whether dysregulation of cell motility (Cdc42 expression), escaping the control of cell-cell and cell-matrix interactions (E-cadherin, beta-catenin expression), enhances melanoma progression, and whether chemokine receptors (CXCR4) mediate cell migration and activation during invasion and metastasis development.METHODSThe immunohistochemical expression of Cdc42, E-cadherin, beta-catenin and CXCR4 was investigated in 30 patients with surgically treated nodular melanoma, 18 alive and disease free and 12 with a fatal outcome due to metastatic disease.RESULTSE-cadherin expression was significantly reduced (P < 0.05) and cytoplasmic beta-catenin was increased in the patients who had died compared with disease-free individuals, while membrane expression of beta-catenin was similar in the two groups. Patients with fatal outcome had increased Cdc42 (P < 0.01) and CXCR4 (P < 0.05). In this group a positive correlation was found between melanocytic Cdc42 expression and Breslow thickness (r = 0.598, P < 0.05) and between CXCR4 expression and Breslow thickness (r = 0.583, P < 0.05).CONCLUSIONSFindings suggest that primary cutaneous melanoma with a high Breslow thickness is characterized by tumour cells with high motility and invasion ability, in line with the hypothesis that low E-cadherin levels and overexpression of Cdc42 and CXCR4 could be prognostic markers of poor outcome.
Author Brancorsini, D.
Pugnaloni, A.
Giacchetti, A.
Tucci, M.G.
Zizzi, A.
Lucarini, G.
Ricotti, G.
Biagini, G.
Author_xml – sequence: 1
  givenname: M.G.
  surname: Tucci
  fullname: Tucci, M.G.
  organization: U.O. Dermatologia, INRCA-IRCCS, Via della Montagnola 164, Ancona, Italy Istologia-Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Tronto 10/A, 60020 Torrette, Ancona, Italy
– sequence: 2
  givenname: G.
  surname: Lucarini
  fullname: Lucarini, G.
  organization: Dipartimento di Neuroscienze, Istituto di Anatomia Patologica, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Lancisi-Salesi-Umberto I, Via Conca 71, 60020 Torrette, Ancona, Italy
– sequence: 3
  givenname: D.
  surname: Brancorsini
  fullname: Brancorsini, D.
  organization: Dipartimento di Neuroscienze, Istituto di Anatomia Patologica, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Lancisi-Salesi-Umberto I, Via Conca 71, 60020 Torrette, Ancona, Italy
– sequence: 4
  givenname: A.
  surname: Zizzi
  fullname: Zizzi, A.
  organization: U.O. Dermatologia, INRCA-IRCCS, Via della Montagnola 164, Ancona, Italy Istologia-Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Tronto 10/A, 60020 Torrette, Ancona, Italy
– sequence: 5
  givenname: A.
  surname: Pugnaloni
  fullname: Pugnaloni, A.
  organization: U.O. Dermatologia, INRCA-IRCCS, Via della Montagnola 164, Ancona, Italy Istologia-Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Tronto 10/A, 60020 Torrette, Ancona, Italy
– sequence: 6
  givenname: A.
  surname: Giacchetti
  fullname: Giacchetti, A.
  organization: U.O. Dermatologia, INRCA-IRCCS, Via della Montagnola 164, Ancona, Italy Istologia-Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Tronto 10/A, 60020 Torrette, Ancona, Italy
– sequence: 7
  givenname: G.
  surname: Ricotti
  fullname: Ricotti, G.
  organization: U.O. Dermatologia, INRCA-IRCCS, Via della Montagnola 164, Ancona, Italy Istologia-Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Tronto 10/A, 60020 Torrette, Ancona, Italy
– sequence: 8
  givenname: G.
  surname: Biagini
  fullname: Biagini, G.
  organization: U.O. Dermatologia, INRCA-IRCCS, Via della Montagnola 164, Ancona, Italy Istologia-Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Tronto 10/A, 60020 Torrette, Ancona, Italy
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19885948$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/17970806$$D View this record in MEDLINE/PubMed
BookMark eNqNkMtO3DAUhq2KCgbKK1TetKsmteP4tuiipEBBqJVGQLuzHOekZJo4NM7Q4bV4EJ6pDhnBtt74HJ3vP5d_H-343gNCmJKUxvdxlVImeJJRxtKMEJkSleUi3bxCi-fCDlqQWEqIFmwP7YewIoQywsku2qNSS6KIWKDuzN_17R104Efc1_g4cba6gaHxH_DjQ0xG8FNcVC7PsPUVLn4Wyxw3Ho83gG-H_tcAITS9fypOue9DE6Zebj1aD_064A5a6_vOvkGva9sGONz-B-jq5Piy-JpcfD89Kz5fJC5nXCSVzazUJK-F1NoJR3MurQJWungXU1aDjUdBlZUKCIFSWF1yJpkqK0Ym6AC9n_vGff6sIYyma4KDtp33MULxjDMiI6hm0A19CAPU5nZoOjvcG0rMZLVZmclRMzlqJqvNk9VmE6VvtzPWZQfVi3DrbQTebQEbnG3rwXrXhBdOK8V1riL3aeb-Ni3c__cC5uj8yxRFfTLrmzDC5llvh99GSCa5-fHt1Fwurynly3Nzwv4BGtiqsA
CODEN BJDEAZ
CitedBy_id crossref_primary_10_1111_pcmr_12544
crossref_primary_10_1111_j_1365_2133_2009_09107_x
crossref_primary_10_1016_j_abb_2011_10_020
crossref_primary_10_1093_jnci_djp038
crossref_primary_10_1111_pcmr_12343
crossref_primary_10_1016_j_ccr_2011_10_030
crossref_primary_10_1021_bm400849n
crossref_primary_10_1007_s00428_012_1309_9
crossref_primary_10_1016_j_canlet_2014_08_033
crossref_primary_10_3892_etm_2018_6413
crossref_primary_10_1016_j_urolonc_2015_03_016
crossref_primary_10_1111_bjd_14720
crossref_primary_10_3390_ijms23094775
crossref_primary_10_1016_j_pharmthera_2017_05_012
crossref_primary_10_1002_1878_0261_12433
crossref_primary_10_1111_j_1468_3083_2011_03978_x
crossref_primary_10_1016_j_cyto_2024_156629
crossref_primary_10_1016_j_jid_2018_09_027
crossref_primary_10_1309_AJCP52YVYCTLUOPI
crossref_primary_10_1002_mco2_144
crossref_primary_10_1111_bjd_12426
crossref_primary_10_1016_j_celrep_2022_110641
crossref_primary_10_1007_s10620_017_4451_z
crossref_primary_10_1097_MNM_0000000000001806
crossref_primary_10_1002_ijc_30785
crossref_primary_10_1128_JVI_00590_15
crossref_primary_10_18632_oncotarget_7393
crossref_primary_10_1016_j_semcancer_2008_10_001
crossref_primary_10_1155_2020_8180261
crossref_primary_10_3390_cancers3010126
crossref_primary_10_17650_1726_9784_2020_19_4_8_17
crossref_primary_10_1038_s41598_017_10891_0
crossref_primary_10_1074_jbc_RA118_003290
crossref_primary_10_1007_s00403_013_1351_8
crossref_primary_10_1016_j_semcancer_2008_10_009
crossref_primary_10_1186_s12967_014_0305_z
crossref_primary_10_3389_fcell_2020_575223
crossref_primary_10_1016_j_bbcan_2012_03_011
crossref_primary_10_1074_jbc_RA119_010077
crossref_primary_10_1016_j_acthis_2008_10_002
crossref_primary_10_1038_jid_2010_149
crossref_primary_10_1111_j_1365_2133_2008_09001_x
crossref_primary_10_1016_j_fertnstert_2012_10_042
crossref_primary_10_1016_j_humpath_2014_06_018
crossref_primary_10_1007_BF03256334
crossref_primary_10_1177_0300985820934385
crossref_primary_10_4161_sgtp_29019
crossref_primary_10_1007_s10585_010_9368_2
crossref_primary_10_1016_j_cellsig_2011_04_001
crossref_primary_10_1371_journal_pone_0037317
crossref_primary_10_1111_j_1365_2133_2009_09395_x
crossref_primary_10_1517_14728222_2013_828037
crossref_primary_10_1111_ajd_12023
crossref_primary_10_1016_j_semcancer_2008_10_012
crossref_primary_10_3892_or_2016_4618
crossref_primary_10_3389_fonc_2020_626129
crossref_primary_10_1038_onc_2013_194
crossref_primary_10_1111_j_1349_7006_2008_00997_x
crossref_primary_10_1074_mcp_M112_027052
crossref_primary_10_3390_ijms18030586
crossref_primary_10_1038_jid_2012_421
crossref_primary_10_1016_j_rvsc_2020_04_007
crossref_primary_10_1038_s41598_022_21342_w
crossref_primary_10_1074_jbc_M112_435941
crossref_primary_10_1002_cjp2_34
crossref_primary_10_1002_ijc_25452
crossref_primary_10_1111_pcmr_12379
crossref_primary_10_1016_j_ajpath_2012_07_009
crossref_primary_10_1620_tjem_2023_J091
crossref_primary_10_1093_carcin_bgt248
crossref_primary_10_1002_ijc_30245
crossref_primary_10_18632_aging_103054
crossref_primary_10_1038_srep29719
crossref_primary_10_1371_journal_pone_0086338
crossref_primary_10_3390_cells9061430
crossref_primary_10_1186_1471_2407_10_113
crossref_primary_10_1111_eci_13964
crossref_primary_10_3390_ijms25073956
crossref_primary_10_18632_oncotarget_15815
crossref_primary_10_1038_labinvest_2012_62
crossref_primary_10_1242_jcs_240135
crossref_primary_10_18632_oncotarget_10205
crossref_primary_10_1002_ptr_7587
crossref_primary_10_1111_j_1440_1827_2010_02548_x
crossref_primary_10_3892_or_2017_5546
crossref_primary_10_18632_oncotarget_14687
crossref_primary_10_1016_j_bcp_2013_09_001
crossref_primary_10_1080_21541248_2016_1173767
crossref_primary_10_3109_1354750X_2013_781677
crossref_primary_10_1080_14737140_2021_1882860
crossref_primary_10_1007_s13277_014_2500_1
crossref_primary_10_1097_CCO_0b013e328337fe8f
Cites_doi 10.1038/35065016
10.1016/j.jdermsci.2004.03.002
10.1158/0008-5472.CAN-03-1757
10.1016/S0002-9440(10)65023-7
10.1038/70302
10.1111/j.1600-0560.2006.00601.x
10.1136/mp.52.3.151
10.1074/jbc.M106912200
10.1046/j.1365-2133.2003.05240.x
10.1038/bjc.1991.375
10.1111/j.1087-0024.2005.200407.x
10.1242/jcs.113.9.1535
10.1158/1078-0432.CCR-04-1887
10.1242/jcs.107.4.983
10.1097/00000658-197011000-00017
10.1006/scbi.2000.0362
10.1126/science.287.5458.1606
10.1016/j.fertnstert.2006.01.031
10.1016/S0014-5793(02)03698-0
10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K
10.1158/1078-0432.CCR-03-0195
ContentType Journal Article
Copyright 2008 INIST-CNRS
Copyright_xml – notice: 2008 INIST-CNRS
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1111/j.1365-2133.2007.08246.x
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2133
EndPage 1216
ExternalDocumentID 10_1111_j_1365_2133_2007_08246_x
17970806
19885948
BJD8246
ark_67375_WNG_TRV115RJ_F
Genre article
Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1CY
1OB
1OC
23N
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
5WD
66C
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AABZA
AACZT
AAESR
AAEVG
AAHHS
AAONW
AAPGJ
AAPXW
AARHZ
AASGY
AAUAY
AAVAP
AAWDT
AAXRX
AAZKR
ABCQN
ABCUV
ABEJV
ABEML
ABNHQ
ABOCM
ABPTD
ABPVW
ABQNK
ABWST
ABXGK
ABXVV
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACFRR
ACGFS
ACMXC
ACPOU
ACPRK
ACSCC
ACUTJ
ACXBN
ACXQS
ACZBC
ADBBV
ADEOM
ADIPN
ADIZJ
ADKYN
ADMGS
ADOZA
ADQBN
ADVEK
ADXAS
ADZMN
ADZOD
AEEZP
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFEBI
AFFNX
AFGKR
AFPWT
AFYAG
AFZJQ
AGMDO
AGQXC
AGUTN
AHEFC
AIACR
AIURR
AIWBW
AJAOE
AJBDE
AJEEA
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
APJGH
ASPBG
ATGXG
ATUGU
AVNTJ
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BCRHZ
BDRZF
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
H13
HF~
HVGLF
HZI
HZ~
IHE
IX1
J0M
J5H
K48
KBYEO
KOP
L7B
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OAUYM
OCZFY
OIG
OJZSN
OPAEJ
OVD
OWPYF
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
ROX
RX1
SUPJJ
TEORI
TMA
UB1
V9Y
VVN
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
X7M
XG1
Y6R
YFH
ZGI
ZXP
ZZTAW
~IA
~WT
08R
AAPBV
AAUGY
AAVGM
ABHUG
ABPTK
ABWRO
ACSMX
ACXME
ADAWD
ADDAD
AFVGU
AGJLS
AKALU
ALXQX
BFHJK
IQODW
OBFPC
SAMSI
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c4356-da2a7904f6799c6c1457a8e3bc13338a9ea963ed2b8e00eb6a9b53738bd30bc13
IEDL.DBID 33P
ISSN 0007-0963
IngestDate Fri Aug 16 22:01:55 EDT 2024
Fri Nov 22 01:13:41 EST 2024
Sat Sep 28 07:51:36 EDT 2024
Sun Oct 29 17:06:19 EDT 2023
Sat Aug 24 00:51:48 EDT 2024
Wed Oct 30 09:56:42 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords cutaneous melanoma
Prognosis
Dermatology
CXCR4
Malignant tumor
E-cadherin
β-caten#m
β Catenin
Malignant melanoma
Evolution
Skin
CXC chemokine
E Cadherin
Cancer
Cdc42
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4356-da2a7904f6799c6c1457a8e3bc13338a9ea963ed2b8e00eb6a9b53738bd30bc13
Notes ArticleID:BJD8246
ark:/67375/WNG-TRV115RJ-F
istex:5D24FF939F353D477390C1F31EB19CA6396D0B79
Conflicts of interest
None declared.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 17970806
PQID 68525307
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_68525307
crossref_primary_10_1111_j_1365_2133_2007_08246_x
pubmed_primary_17970806
pascalfrancis_primary_19885948
wiley_primary_10_1111_j_1365_2133_2007_08246_x_BJD8246
istex_primary_ark_67375_WNG_TRV115RJ_F
PublicationCentury 2000
PublicationDate December 2007
PublicationDateYYYYMMDD 2007-12-01
PublicationDate_xml – month: 12
  year: 2007
  text: December 2007
PublicationDecade 2000
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: London
– name: Oxford
– name: Edinburgh
– name: England
PublicationTitle British journal of dermatology (1951)
PublicationTitleAlternate Br J Dermatol
PublicationYear 2007
Publisher Blackwell Publishing Ltd
Blackwell
Publisher_xml – name: Blackwell Publishing Ltd
– name: Blackwell
References Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis: a look outside the nucleus. Science 2000; 287:1606-9.
Sanders DS, Blessing K, Hassan GA et al. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. Mol Pathol 1999; 52:151-7.
Oyama T, Kanai Y, Ochiai A et al. A truncated β-catenin disrupts the interaction between E-cadherin and α-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines. Cancer Res 1994; 54:6282-7.
Tang A, Eller MS, Hara M et al. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J Cell Sci 1994; 107:983-92.
Kassis J, Lauffenburger DA, Turner T, Wells A. Tumor invasion as dysregulated cell motility. Semin Cancer Biol 2001; 11:105-17.
Jung ID, Lee J, Yun SY et al. Cdc42 and Rac1 are necessary for autotaxin-induced tumor cell motility in A2058 melanoma cells. FEBS Lett 2002; 532:351-6.
Murakami T, Cardones AR, Hwang ST. Chemokine receptors and melanoma metastasis. J Dermatol Sci 2004; 36:71-8.
Hsu MY, Meier FE, Nesbit M et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 2000; 156:1515-25.
Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705-27.
Robledo MM, Bartolomè RA, Longo N et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001; 276:45098-105.
El-Bahrawy M, El-Masry N, Alison M et al. Expression of β-catenin in basal cell carcinoma. Br J Dermatol 2003; 148:964-70.
Goteri G, Ciavattini A, Lucarini G et al. Expression of motility-related molecule Cdc42 in endometrial tissue of women with adenomyosis and ovarian endometriomata. Fertil Steril 2006; 86:559-65.
Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902-8.
Takeuchi H, Fujimoto A, Tanaka M et al. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 2004; 10:2351-8.
Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 2005; 10:153-63.
Silye R, Karayiannakis AJ, Syrigos KN et al. E-cadherin/catenin complex in benign and malignant melanocytic lesions. J Pathol 1998; 186:350-5.
Hsu M, Andl T, Li G et al. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci 2000; 113:1535-42.
Scala S, Ottaviano A, Ascierto PA et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 11:1835-41.
Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-6.
Pecina-Slaus N, Zigmund M, Kusec V et al. E-cadherin and β-catenin expression patterns in malignant melanoma assessed by image analysis. J Cutan Pathol 2007; 34:239-46.
Kawada K, Sonoshita M, Sakashita H et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004; 64:4010-17.
Meier F, Satyamoorthy K, Nesbit M et al. Molecular events in melanoma development and progression. Front Biosci 1988; 3:D1005-10.
Murakami T, Maki W, Cardones AR et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002; 62:7328-34.
Eisenmann KM, McCarthy JB, Simpson MA et al. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1999; 1:507-13.
Clark WH. Tumour progression and the nature of cancer. Br J Cancer 1991; 64:631-44.
2004; 64
2000; 113
2002; 532
2000; 156
1999; 1
2007; 34
2001; 276
2004; 10
2001; 410
1988; 3
2006; 86
2002; 62
1970; 172
2004; 36
1991; 64
2005; 10
1999; 52
2000; 287
1969; 29
2001; 11
2003; 148
1994; 107
2005; 11
1998; 186
1994; 54
b7_1005
b19_1017
b16_1014
b13_1011
Oyama T (b8_1006) 1994; 54
Meier F (b1_999) 1988; 3
b22_1020
b25_1023
b10_1008
b15_1013
b4_1002
b20_1018
b24_1022
Sanders DS (b3_1001) 1999; 52
Clark WH (b14_1012) 1969; 29
b17_1015
Clark WH (b2_1000) 1991; 64
Hsu M (b18_1016) 2000; 113
Tang A (b5_1003) 1994; 107
b9_1007
b11_1009
Hsu MY (b6_1004) 2000; 156
Murakami T (b12_1010) 2002; 62
b23_1021
b21_1019
References_xml – volume: 113
  start-page: 1535
  year: 2000
  end-page: 42
  article-title: Cadherin repertoire determines partner‐specific gap junctional communication during melanoma progression
  publication-title: J Cell Sci
– volume: 276
  start-page: 45098
  year: 2001
  end-page: 105
  article-title: Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells
  publication-title: J Biol Chem
– volume: 10
  start-page: 153
  year: 2005
  end-page: 63
  article-title: Normal human melanocyte homeostasis as a paradigm for understanding melanoma
  publication-title: J Investig Dermatol Symp Proc
– volume: 36
  start-page: 71
  year: 2004
  end-page: 8
  article-title: Chemokine receptors and melanoma metastasis
  publication-title: J Dermatol Sci
– volume: 3
  start-page: D1005
  year: 1988
  end-page: 10
  article-title: Molecular events in melanoma development and progression
  publication-title: Front Biosci
– volume: 11
  start-page: 105
  year: 2001
  end-page: 17
  article-title: Tumor invasion as dysregulated cell motility
  publication-title: Semin Cancer Biol
– volume: 29
  start-page: 705
  year: 1969
  end-page: 27
  article-title: The histogenesis and biologic behavior of primary human malignant melanomas of the skin
  publication-title: Cancer Res
– volume: 64
  start-page: 4010
  year: 2004
  end-page: 17
  article-title: Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes
  publication-title: Cancer Res
– volume: 186
  start-page: 350
  year: 1998
  end-page: 5
  article-title: E‐cadherin/catenin complex in benign and malignant melanocytic lesions
  publication-title: J Pathol
– volume: 532
  start-page: 351
  year: 2002
  end-page: 6
  article-title: Cdc42 and Rac1 are necessary for autotaxin‐induced tumor cell motility in A2058 melanoma cells
  publication-title: FEBS Lett
– volume: 62
  start-page: 7328
  year: 2002
  end-page: 34
  article-title: Expression of CXC chemokine receptor‐4 enhances the pulmonary metastatic potential of murine B16 melanoma cells
  publication-title: Cancer Res
– volume: 1
  start-page: 507
  year: 1999
  end-page: 13
  article-title: Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack‐1 and p130
  publication-title: Nat Cell Biol
– volume: 156
  start-page: 1515
  year: 2000
  end-page: 25
  article-title: E‐cadherin expression in melanoma cells restores keratinocyte‐mediated growth control and down‐regulates expression of invasion‐related adhesion receptors
  publication-title: Am J Pathol
– volume: 34
  start-page: 239
  year: 2007
  end-page: 46
  article-title: E‐cadherin and β‐catenin expression patterns in malignant melanoma assessed by image analysis
  publication-title: J Cutan Pathol
– volume: 148
  start-page: 964
  year: 2003
  end-page: 70
  article-title: Expression of β‐catenin in basal cell carcinoma
  publication-title: Br J Dermatol
– volume: 11
  start-page: 1835
  year: 2005
  end-page: 41
  article-title: Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma
  publication-title: Clin Cancer Res
– volume: 52
  start-page: 151
  year: 1999
  end-page: 7
  article-title: Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours
  publication-title: Mol Pathol
– volume: 287
  start-page: 1606
  year: 2000
  end-page: 9
  article-title: Wnt signaling in oncogenesis and embryogenesis: a look outside the nucleus
  publication-title: Science
– volume: 64
  start-page: 631
  year: 1991
  end-page: 44
  article-title: Tumour progression and the nature of cancer
  publication-title: Br J Cancer
– volume: 54
  start-page: 6282
  year: 1994
  end-page: 7
  article-title: A truncated β‐catenin disrupts the interaction between E‐cadherin and α‐catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines
  publication-title: Cancer Res
– volume: 86
  start-page: 559
  year: 2006
  end-page: 65
  article-title: Expression of motility‐related molecule Cdc42 in endometrial tissue of women with adenomyosis and ovarian endometriomata
  publication-title: Fertil Steril
– volume: 172
  start-page: 902
  year: 1970
  end-page: 8
  article-title: Thickness, cross‐sectional areas and depth of invasion in the prognosis of cutaneous melanoma
  publication-title: Ann Surg
– volume: 410
  start-page: 50
  year: 2001
  end-page: 6
  article-title: Involvement of chemokine receptors in breast cancer metastasis
  publication-title: Nature
– volume: 107
  start-page: 983
  year: 1994
  end-page: 92
  article-title: E‐cadherin is the major mediator of human melanocyte adhesion to keratinocytes
  publication-title: J Cell Sci
– volume: 10
  start-page: 2351
  year: 2004
  end-page: 8
  article-title: CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells
  publication-title: Clin Cancer Res
– ident: b13_1011
  doi: 10.1038/35065016
– ident: b23_1021
  doi: 10.1016/j.jdermsci.2004.03.002
– ident: b25_1023
  doi: 10.1158/0008-5472.CAN-03-1757
– volume: 156
  start-page: 1515
  year: 2000
  ident: b6_1004
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)65023-7
  contributor:
    fullname: Hsu MY
– ident: b20_1018
  doi: 10.1038/70302
– ident: b16_1014
  doi: 10.1111/j.1600-0560.2006.00601.x
– volume: 52
  start-page: 151
  year: 1999
  ident: b3_1001
  publication-title: Mol Pathol
  doi: 10.1136/mp.52.3.151
  contributor:
    fullname: Sanders DS
– volume: 29
  start-page: 705
  year: 1969
  ident: b14_1012
  publication-title: Cancer Res
  contributor:
    fullname: Clark WH
– ident: b22_1020
  doi: 10.1074/jbc.M106912200
– ident: b19_1017
  doi: 10.1046/j.1365-2133.2003.05240.x
– volume: 64
  start-page: 631
  year: 1991
  ident: b2_1000
  publication-title: Br J Cancer
  doi: 10.1038/bjc.1991.375
  contributor:
    fullname: Clark WH
– volume: 54
  start-page: 6282
  year: 1994
  ident: b8_1006
  publication-title: Cancer Res
  contributor:
    fullname: Oyama T
– ident: b17_1015
  doi: 10.1111/j.1087-0024.2005.200407.x
– volume: 113
  start-page: 1535
  year: 2000
  ident: b18_1016
  publication-title: J Cell Sci
  doi: 10.1242/jcs.113.9.1535
  contributor:
    fullname: Hsu M
– ident: b21_1019
  doi: 10.1158/1078-0432.CCR-04-1887
– volume: 107
  start-page: 983
  year: 1994
  ident: b5_1003
  publication-title: J Cell Sci
  doi: 10.1242/jcs.107.4.983
  contributor:
    fullname: Tang A
– ident: b15_1013
  doi: 10.1097/00000658-197011000-00017
– ident: b9_1007
  doi: 10.1006/scbi.2000.0362
– ident: b7_1005
  doi: 10.1126/science.287.5458.1606
– volume: 3
  start-page: D1005
  year: 1988
  ident: b1_999
  publication-title: Front Biosci
  contributor:
    fullname: Meier F
– ident: b11_1009
  doi: 10.1016/j.fertnstert.2006.01.031
– ident: b10_1008
  doi: 10.1016/S0014-5793(02)03698-0
– volume: 62
  start-page: 7328
  year: 2002
  ident: b12_1010
  publication-title: Cancer Res
  contributor:
    fullname: Murakami T
– ident: b4_1002
  doi: 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K
– ident: b24_1022
  doi: 10.1158/1078-0432.CCR-03-0195
SSID ssj0013050
Score 2.2790024
Snippet Summary Background  A key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of...
A key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may be viewed...
BACKGROUNDA key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may...
SourceID proquest
crossref
pubmed
pascalfrancis
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 1212
SubjectTerms Adult
Aged
beta Catenin - physiology
Biological and medical sciences
Cadherins - physiology
Cdc42
cdc42 GTP-Binding Protein - physiology
Cell Proliferation
cutaneous melanoma
CXCR4
Dermatology
Disease Progression
E-cadherin
Female
Gene Expression Profiling
Humans
Immunohistochemistry - methods
Male
Medical sciences
Melanoma - etiology
Middle Aged
Prognosis
Receptors, CXCR4 - physiology
Skin Neoplasms - etiology
Tumors of the skin and soft tissue. Premalignant lesions
β-catenin
Title Involvement of E-cadherin, β-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma
URI https://api.istex.fr/ark:/67375/WNG-TRV115RJ-F/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2133.2007.08246.x
https://www.ncbi.nlm.nih.gov/pubmed/17970806
https://search.proquest.com/docview/68525307
Volume 157
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB5BkRAXyj_hp_iAOBHkTRzbOcJ2l7ISFVoK9GbZjiNV0ASartRjH4Fn4UH6EH0SZpzdLpF6QIhbrNhOPJ6xP9sznwGe54q74IRLC-54KiyqsS29S23hfUB8iyCWYod3Pqrdfb09IZqc2SoWpueHuNhwI8uI4zUZuHXd0MijhxYuspZMhDoT8hXhSVw0xGiO_MP6QIEXfTQK7cyh0g2dei6taDBTXSOhn5DnpO1QeHV_68VlsHSIcuM0Nd38nw28BTeXYJW97rXrNlwJzR24_n55HH8XfrxrcHSLjOPHrK3Z5Pz0p7dVDCl8yc5-xSSCckqNKy8yZpuKjffHc8EOGobYk0X_sJ4bJL6kdNN2Bx3V5xcIXUO76Nhh-Gab9tDeg0_Tyd54J13e4ZB6BGIyrWxmVclFLVVZeulHolBWh9x5bFaubRks9kaoMqcD58FJW7qC2JZclXPKdB82mrYJD4HJkVSI_1Sdi1qMXOZQOlWee8mzYLXVCYxW_WW-91Qd5o8lDuY2JEu6eFOZKEtzksCL2LEXBezRV3J1U4X5svvW7M0_I2Kez8w0ga1Bz6-_UGpNlDcJPFupgkELpWOXXkJG6iIrcChN4EGvIeuyqlSI2GUCMirCX_-2eTPbpqdH_1rwMdyIm9TRL-cJbBwfLcJTuNpVi61oN78Bpu0Ugw
link.rule.ids 315,782,786,1408,27933,27934,46064,46488
linkProvider Wiley-Blackwell
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB5BKwEX_kvDT-sD4kRQNnFs5wjbXbZ_K7Qs0JtlO45UQZPSdKUeeQSehQfhIXgSZpzdLiv1gBC3WLGdeH7sz-OZMcDzTCbWW27jPLFJzA2KsSmcjU3unEd8iyCWYodH7-X4SO0MKE3O_iIWpssPcWlwI80I8zUpOBmkV7U8uGjhLmueilClXLxCQLnOBcolxXNk75ZHCknexaOQbQ7FbtWt58qeVtaqdSL7BflOmhbJV3X3XlwFTFdxbliohnf-6xDvwu05XmWvOwG7B9d8fR9uHM5P5B_A190aJ7iQdPycNRUb_Pr23ZkyRBW-ZD9_hCLicir1S8dTZuqS9Y_6E86Oa4bwkwUXsS49SHhJ5bppj1vqz80Qvfpm1rIT_8XUzYl5CB-Gg2l_FM-vcYgdYjERlyY1skh4JWRROOF6PJdG-cw6HFamTOENssOXqVU-SbwVprA5JVyyZZZQpQ1Yq5vabwITPSERAsoq4xXv2dQidcoscyJJvVFGRdBbMEyfdtk69B-7HKytiZZ096bUgZb6IoIXgbOXDczZZ_J2k7n-NH6rp5OPCJone3oYwdYK65dfKJSirDcRbC9kQaOS0slLRyEtVJ7mOJtG8KgTkWVbWUgE7SICESThr39bv9nboafH_9pwG26OpocH-mB3vP8EbgWbdXDTeQpr52cz_wyut-VsKyjRbydYGKs
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB5BK1Vc-P8JP60PiBNB2cSxnSPsD-0Cq2op0JtlO45UQZPSdKUeeQSehQfhIXgSZpzdLpF6QIhbrNhOPJ6xP9sznwGeZjKx3nIb54lNYm5QjU3hbGxy5zziWwSxFDu8-17ODtVoTDQ501UsTMcPcbHhRpYRxmsy8JOy6ht58NDCRdaSiVClXLxAPLnJEZUTj36W7a9PFJK8C0ehrTnUur5Xz6U19aaqTZL6OblOmhalV3XXXlyGS_swN8xTkxv_s4U34foSrbKXnXrdgiu-vg1b75bn8Xfg616Nw1ugHD9jTcXGv759d6YMMYXP2c8fIYmonFLD0vGUmbpkw8PhnLOjmiH4ZMFBrCMHCS8pXTftUUv1uQViV98sWnbsv5i6OTZ34cNkfDDcjZeXOMQOkZiIS5MaWSS8ErIonHADnkujfGYdNitTpvAGe8OXqVU-SbwVprA50S3ZMkso0z3YqJvaPwAmBkIiAJRVxis-sKlF6ZRZ5kSSeqOMimCw6i990nF16D_WOJhbkyzp5k2pgyz1eQTPQsdeFDCnn8nXTeb60-y1Pph_RMg8n-pJBNu9nl9_oVCKOG8i2FmpgkYTpXOXTkJaqDzNcSyN4H6nIeuyspAI2UUEIijCX_-2fjUd0dPDfy24A1v7o4l-uzd78wiuhQ3r4KPzGDbOThf-CVxty8V2MKHfl2sXUQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Involvement+of+E%E2%80%90cadherin%2C+%CE%B2%E2%80%90catenin%2C+Cdc42+and+CXCR4+in+the+progression+and+prognosis+of+cutaneous+melanoma&rft.jtitle=British+journal+of+dermatology+%281951%29&rft.au=Tucci%2C+M.G.&rft.au=Lucarini%2C+G.&rft.au=Brancorsini%2C+D.&rft.au=Zizzi%2C+A.&rft.date=2007-12-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0007-0963&rft.eissn=1365-2133&rft.volume=157&rft.issue=6&rft.spage=1212&rft.epage=1216&rft_id=info:doi/10.1111%2Fj.1365-2133.2007.08246.x&rft.externalDBID=10.1111%252Fj.1365-2133.2007.08246.x&rft.externalDocID=BJD8246
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0963&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0963&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0963&client=summon